


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of the following Formula I:



I

wherein:

R<sub>1</sub> has the formula alkylene-L-R<sub>1-1</sub>, alkenylene-L-R<sub>1-1</sub>, or alkynylene-L-R<sub>1-1</sub>, wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of -NH-S(O)<sub>2</sub>-, -NH-C(O)-, -NH-C(S)-, -NH-S(O)<sub>2</sub>-NR<sub>3</sub>-, -NH-C(O)-NR<sub>3</sub>-, -NH-C(S)-NR<sub>3</sub>-, -NH-C(O)-O-, -O-, -S-, and -S(O)<sub>2</sub>-; and

R<sub>1-1</sub> is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R'' is selected from the group consisting of:

\_\_\_\_\_ hydrogen;

\_\_\_\_\_ alkyl;

\_\_\_\_\_ alkenyl;

\_\_\_\_\_ aryl;

\_\_\_\_\_ heteroaryl;

\_\_\_\_\_ heterocyclyl;

\_\_\_\_\_ alkylene-Y-alkyl;

\_\_\_\_\_ alkylene-Y-alkenyl;

alkylene-Y-aryl; and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

\_\_\_\_\_ -OH;  
 \_\_\_\_\_ halogen;  
 \_\_\_\_\_ -N(R<sub>4</sub>)<sub>2</sub>;  
 \_\_\_\_\_ -C(O)-C<sub>1-10</sub>alkyl;  
 \_\_\_\_\_ -C(O)-O-C<sub>1-10</sub>alkyl;  
 \_\_\_\_\_ -N<sub>3</sub>;  
 \_\_\_\_\_ aryl;  
 \_\_\_\_\_ heteroaryl;  
 \_\_\_\_\_ heterocyclyl;  
 \_\_\_\_\_ -C(O)-aryl; and  
 \_\_\_\_\_ -C(O)-heteroaryl;

wherein: Y is -O- or -S(O)<sub>0-2</sub>; and each R<sub>4</sub> is independently selected from the group consisting of hydrogen, C<sub>1-10</sub>alkyl, and C<sub>2-10</sub>alkenylhydrogen or a non-interfering substituent;

R<sub>A</sub> and R<sub>B</sub> are each independently selected from the group consisting of:

hydrogen,  
 halogen,  
 alkyl,  
 alkenyl,  
 alkoxy,  
 alkylthio, and  
 -N(R<sub>3</sub>)<sub>2</sub>;

or when taken together, R<sub>A</sub> and R<sub>B</sub> form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups;

or when taken together, R<sub>A</sub> and R<sub>B</sub> form a fused 5- to 7-membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;

each R is independently selected from the group consisting of

halogen,hydroxy,alkyl,alkenyl,haloalkyl,alkoxy,alkylthio, and

$-N(R_3)_2$ ,  $R_A$  and  $R_B$  form a fused aryl ring or heteroaryl ring containing one heteroatom or a fused 5- to 7-membered saturated ring, optionally containing one heteroatom, wherein the heteroatom is selected from the group consisting of N and S, and wherein the aryl, heteroaryl, or 5- to 7-membered saturated ring is unsubstituted or substituted by one or more non-interfering substituents; and

each  $R_3$  is independently selected from the group consisting of hydrogen and alkyl;

with the proviso that when L is  $-NH-S(O)_2-$  and  $R_A$  and  $R_B$  join to form an unsubstituted benzene ring,  $R_{1-1}$  is a linear or branched aliphatic group having greater than 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; and with the further proviso that when L is  $-NH-C(O)-$  and  $R_A$  and  $R_B$  join to form an unsubstituted pyridine ring,  $R_{1-1}$  is a linear or branched aliphatic group having greater than 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;  
or a pharmaceutically acceptable salt thereof.

2-6 (canceled)

7. (currently amended) The compound or salt of claim 16 wherein  $R_A$  and  $R_B$  form a fused benzene ring which is unsubstituted.

8-10 (canceled)

11. (currently amended) The compound or salt of claim 10 wherein L is a bond or a functional linking group selected from the group consisting of  $-NH-C(O)-$ ,  $-NH-S(O)_2-$ , and  $-NH-C(O)-N(R_3)-$ .

12 (canceled)

13. (currently amended) The compound or salt of claim 12 wherein  $R_{1-1}$  is a linear or branched aliphatic group having 12-20 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds.

14. (original) The compound or salt of claim 13 wherein  $R_{1-1}$  is a straight chain  $C_{12}$ - $C_{20}$ alkyl.


15-16 (canceled)

17. (currently amended) The compound or salt of claim 16 wherein  $R_1$  has the formula  $C_{1-5}$ alkylene-L- $R_{1-1}$  and the  $C_{1-5}$ alkylene is optionally interrupted with one -O- group.

18. (currently amended) The compound or salt of claim 15 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, and alkylene-O-alkyl.

19 (canceled)

20. (original) A compound of the following Formula III:



III

wherein:

$R_1$  has the formula alkylene-L- $R_{1-1}$ , alkenylene-L- $R_{1-1}$ , or alkynylene-L- $R_{1-1}$ , wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of  $\text{-NH-S(O)}_2\text{-}$ ,  $\text{-NH-C(O)-}$ ,  $\text{-NH-C(S)-}$ ,  $\text{-NH-S(O)}_2\text{-NR}_3\text{-}$ ,  $\text{-NH-C(O)-NR}_3\text{-}$ ,  $\text{-NH-C(S)-NR}_3\text{-}$ ,  $\text{-NH-C(O)-O-}$ ,  $\text{-O-}$ ,  $\text{-S-}$ , and  $\text{-S(O)}_2\text{-}$ ; and

$\text{R}_{1-1}$  is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R is selected from the group consisting of

halogen,  
hydroxy,  
alkyl,  
alkenyl,  
haloalkyl,  
alkoxy,  
alkylthio, and  
 $\text{-N(R}_3)_2$ ;

n is 0 to 4;

$\text{R}_2$  is selected from the group consisting of:

hydrogen;  
alkyl;  
alkenyl;  
aryl;  
heteroaryl;  
heterocyclyl;  
alkylene-Y-alkyl;  
alkylene-Y-alkenyl;  
alkylene-Y-aryl; and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

$\text{-OH}$ ;  
halogen;  
 $\text{-N(R}_4)_2$ ;  
 $\text{-C(O)-C}_{1-10}\text{alkyl}$ ;

-C(O)-O-C<sub>1-10</sub>alkyl;

-N<sub>3</sub>;

aryl;

heteroaryl;

heterocyclyl;

-C(O)-aryl; and

-C(O)-heteroaryl;

Y is -O- or -S(O)<sub>0-2</sub>;

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, C<sub>1-10</sub>alkyl, and C<sub>2-10</sub>alkenyl; and

R<sub>3</sub> is selected from the group consisting of hydrogen and alkyl;

with the proviso that when L is -NH-S(O)<sub>2</sub>-, and n is 0, R<sub>1-1</sub> is a linear or branched aliphatic group having at least 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

or a pharmaceutically acceptable salt thereof.

21. (original) The compound or salt of claim 20 wherein n is 0.

22-23 (canceled)

24. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 23~~ in combination with a pharmaceutically acceptable carrier.

25. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of ~~any one of claims 1 through 23~~ to the animal.

26-27 (canceled)

28. (currently amended) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of ~~any one of claims 1 through 23~~ to the animal as a vaccine adjuvant.

29. (currently amended) A method of vaccinating an animal comprising administering an effective amount of *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)hexadecanamide to the animal as a vaccine adjuvant.

30-32 (canceled)

33. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 20 in combination with a pharmaceutically acceptable carrier.

34. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal.

35. (new) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal as a vaccine adjuvant.